Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2020.00660OncologyMini ReviewAdenylate Kinase and Metabolic Signaling in Cancer CellsKlepininAleksandr1*ZhangSong2KlepininaLjudmila1Rebane-KlemmEgle1TerzicAndre2KaambreTuuli1DzejaPetras2*1Laboratory of Chemical Biology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia2Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States
Edited by: Stefano Falone, University of L'Aquila, Italy
Reviewed by: Daria Capece, Imperial College London, United Kingdom; Paul Dent, Virginia Commonwealth University, United States; Elisabetta Benedetti, University of L'Aquila, Italy
*Correspondence: Aleksandr Klepinin aleksandr.klepinin@kbfi.eePetras Dzeja dzeja.petras@mayo.edu
This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A hallmark of cancer cells is the ability to rewire their bioenergetics and metabolic signaling circuits to fuel their uncontrolled proliferation and metastasis. Adenylate kinase (AK) is the critical enzyme in the metabolic monitoring of cellular adenine nucleotide homeostasis. It also directs AK→ AMP→ AMPK signaling controlling cell cycle and proliferation, and ATP energy transfer from mitochondria to distribute energy among cellular processes. The significance of AK isoform network in the regulation of a variety of cellular processes, which include cell differentiation and motility, is rapidly growing. Adenylate kinase 2 (AK2) isoform, localized in intermembrane and intra-cristae space, is vital for mitochondria nucleotide exchange and ATP export. AK2 deficiency disrupts cell energetics, causes severe human diseases, and is embryonically lethal in mice, signifying the importance of catalyzed phosphotransfer in cellular energetics. Suppression of AK phosphotransfer and AMP generation in cancer cells and consequently signaling through AMPK could be an important factor in the initiation of cancerous transformation, unleashing uncontrolled cell cycle and growth. Evidence also builds up that shift in AK isoforms is used later by cancer cells for rewiring energy metabolism to support their high proliferation activity and tumor progression. As cell motility is an energy-consuming process, positioning of AK isoforms to increased energy consumption sites could be an essential factor to incline cancer cells to metastases. In this review, we summarize recent advances in studies of the significance of AK isoforms involved in cancer cell metabolism, metabolic signaling, metastatic potential, and a therapeutic target.
The significance of metabolism and metabolic signaling in human diseases is rapidly growing. New features and molecular players that are vital for cell homeostasis and function are being uncovered. Well-organized high-energy phosphoryl transfer systems are required to mediate intracellular communication between ATP-consuming and ATP-producing cellular compartments and thus to maintain normal growth and development of the cell (1–5). The main components of the cellular phosphotransfer system are AK, creatine kinase (CK), and glycolytic networks (1, 2). The significance of organized phosphotransfer was demonstrated by genetic manipulations in animal models, cellular systems, and alterations or mutations in separate phosphotransfer enzymes, which are associated with human diseases (6–16). Studies on Drosophila and mice model demonstrate that deletion of adenylate kinase 2 (AK2) is embryonically lethal, signifying the importance of AK phosphotransfer network in cell homeostasis (13, 17–19). In humans, mutations in the mitochondrial AK2 gene are associated with reticular dysgenesis characterized by immunodeficiency and sensorineural deafness, where processes of nucleotide signaling, cell differentiation, and motility are affected (15, 16, 20). So far, nine isoforms of adenylate kinase (AK1–AK9) and several subforms have been found and well characterized in mammalian cells (21). AK, which catalyzes reaction 2ADP↔AMP+ATP, is a recognized facilitator of AMP metabolic signaling, optimizing intracellular energetic communication, and local ATP supply (5, 22). Historically, the function of AK has been ascribed to de novo adenine nucleotide synthesis and cell energy economy through regulation of nucleotide ratios in different intracellular compartments and AMP-sensitive metabolic enzymes (14, 23, 24). The unique properties of AK lie on its ability to deliver γ- and β-phosphoryl groups of ATP, thereby doubling the ATP energetic potential. Moreover, the AK network provides an efficient mechanism for high-energy phosphoryl transport from mitochondria to ATP utilization sites (2). Evolutionary AK isoforms have been positioned to different subcellular compartments (21, 25). AK1, AK7, and AK8 are solely found in the cytosol; AK2, AK3, and AK4 are located in the mitochondria; and AK5 and AK9 can be found in either the cytosol or nucleus. Only AK1 and AK6 are known to be expressed in all tissues, whereas AK5 is expressed only in the brain (21). In the cytosol, the main isoform is AK1, which is predominantly expressed in high energy demand tissues such as the brain, heart, and skeletal muscles. AK2 is strategically located in the mitochondrial intermembrane and cristae space to facilitate high-energy phosphoryl exchange between mitochondria and cytosol (22). Two other AK isoforms, AK3 and AK4, are located in the mitochondrial matrix and are involved in the regulation of mitochondrial Krebs cycle and oxidative phosphorylation (OXPHOS), whereas AK5 and AK6 isoforms that are localized in the nucleus could serve to fulfill the energy needs of nuclear processes. In general, distinct intracellular localization and kinetic properties of AK isoforms favor energy support of specific cellular processes ranging from muscle contraction, electrical activity, cell motility, unfolded protein response, and mitochondrial/nuclear energetics (22). Importantly, reprogramming of energy metabolism has been proposed as one of the hallmarks of cancer (26), which is required to drive biosynthesis pathways necessary for rapid cell replication and proliferation. Cancer cells are believed to have a greater reliance on glycolytic phosphotransfer (27, 28). However, during the last decade, it was found that some tumors contain numerous mitochondria producing ATP predominantly via OXPHOS (29–31). The observed shift in hexokinase (HK) isoforms, upregulation of HK2 in cancer cells (32), indicates a closer integration of mitochondria with glycolytic phosphotransfer (see Figure 1). The association of HK2 with mitochondria and expression of pyruvate kinase PKM2 could promote effective yet uncontrolled energy distribution in cancer cells (27, 33, 34). Phosphotransfer enzymes such as CK and AK have been implicated in cancer cell proliferation (35, 36). However, it is not clear whether the redistribution of phosphotransfer enzymes, especially those which are localized in mitochondria, occurs during cancer formation. In this review, we focus on the significance of AK isoforms in the rewiring of cancer cell energy metabolism and AMP signaling. Specifically, we will overview how AK isoforms, localized in mitochondria (AK2 and AK4), and their main communication partners cytosolic AK (AK1 and AK6) are involved in cancer formation and metastasis.
Overview of adenylate kinase (AK) isoform involvement in the rewiring of cancer cell metabolic signaling and energetic circuits. Increased competition for cytosolic ADP downregulates AK-mediated AMP signaling, reducing control over cell cycle and proliferation. AK expression is downregulated in several tumors. AMP can be consumed by AMPD and by 5′-NT, also overexpressed in some cancer cells. Augmented glycolytic metabolism, owing to higher affinity, scavenges cytosolic ADP, and uses mitochondrial ATP to drive glucose conversion to lactate. Overexpression of glycolytic HK2, PKM2, and LDHA and mitochondrial ANT2, AK2, AK4, and other genes in cancer cells promotes rewiring of energetic circuits resulting in unrestrained energy distribution. The result of these metabolic transformations is deficient AMP signaling and AMPK-mediated control of cellular katabolic and anabolic processes. Red color indicates the augmented pathways and gene expression in cancer cells. AMPD, AMP-deaminase; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; ANT2, adenine nucleotide translocase 2; AMPK, AMP-activated protein kinase.
Adenylate Kinase 2 and Mitochondrial Creatine Kinase Interplay in Malignant Transformation
AK2 and mitochondrial CK (CKmit) are major phosphotransfer enzymes located in the intermembrane/cristae space in mitochondria (3, 14, 22). AK2 and CKmit provide nucleotide exchange and metabolic signaling capacity, allowing mitochondria to export ATP and reception of cytosolic feedback signals such as ADP, AMP, and creatine (22, 23, 37). Phosphotransfer enzymes CK and AK have been implicated in cancer cell proliferation (35, 36). In general, CK is involved in cancerous transformation, as CKB (brain-type CK) is upregulated in a variety of cancers to support growing energy needs (38). The elevation of creatine metabolites was noted in drug-resistant cancer cells (39). However, in other cancer types, the downregulation of CKB and rewiring of metabolism may play an important role in colon cancer progression (40). Moreover, several studies have demonstrated that in colorectal cancer (41), breast cancer (42), neuroblastoma (35), prostate cancer (43), and sarcoma (36, 44), the CKmit was downregulated. The reduction of CKmit in cancer cells was associated with the upregulation of adenylate kinase AK2 isoform in intermembrane space (36, 41, 42, 45, 46) (see Table 1). There is evidence that the expression of AK2 on the cell surface could facilitate nucleotide signaling and metastatic potential (60). It was found that Ak2 gene expression is upregulated in the metastatic pancreatic endocrine neoplasms (60), indicating the significance of nucleotide metabolic signaling in cancer invasion (61). Moreover, increased expression of the Ak2 on the surface of the metastatic F9DR murine terato-carcinoma cells compared with the nonmetastatic F9B9 cell line has been demonstrated (53). Furthermore, a recent study showed that AK2 has prognostic and therapeutic potential in lung adenocarcinoma (55). The knockdown of AK2 suppressed proliferation, migration, and invasion, as well as induced apoptosis and autophagy in human lung adenocarcinoma cells. In this regard, the AK2-FADD (Fas-associated protein with death domain) mediated apoptosis pathway was found to be defective in some tumor cells, which may contribute to tumor development by preventing apoptosis (62). A recent study indicates that AK2 and FADD are crucial for caspase-10 activation upon metabolic stress, and this activation is independent of death receptors and extrinsic pathway of apoptosis (63). Moreover, the deletion of the Ak2 gene or exit AK2 from mitochondria during apoptosis disrupts nucleotide exchange between mitochondria and cytosol, causing hyperpolarization of mitochondria and reactive oxygen species (ROS) production (20). It was found that the presence of AK2 in mitochondrial cristae nanochannels is critical for ATP export (2, 22). There are evidence that the AK2 upregulation could be used by cancer cells to support energy supply to biosynthetic processes and cellular growth (18, 64). These results, as well as studies on CK and AK knockout mice, demonstrate remarkable plasticity of cellular energetics and phosphotransfer systems, which could be used in cancer cells to promote uncontrolled cell growth (9, 17, 22, 65).
Adenylate kinase isoforms in cancer.
Enzyme
Type of cancer
Status in tumor
Localization
Function/therapeutic target
Experimental model
References
AK
Lung cancer
↓
-
Negative regulator of cancer
Tissue samples
(47)
AK
Hepatomas
↓
-
Decreased during de-differentiation of cancer cells
Rat liver and hepatomas
(48)
AK
Colon cancer
↑
-
Metabolic regulator. Energy distribution shifts from CK toward AK
Estrogen receptor-negative breast cancer tissue samples
(51)
AK2
Breast cancer
↑
Mitochondria intermembrane space
Oncotarget of the breast CSC
Breast CSC
(52)
AK2
Breast cancer and neuroblastoma
↑
Mitochondria intermembrane space
Oncotarget of the poorly differentiated cancer cells
Tissue samples and cancer cell lines
(46)
AK2
Embryonic carcinoma
↑
Mitochondria intermembrane space
Metabolic regulator. Energy distribution shifts from CK toward AK
Cell lines
(36)
AK2
Teratocarcinoma
↑
Plasma membrane
Overexpressed on the plasma membrane in metastatic cells
Cell lines
(53)
AK2
Breast cancer
↓
Nuclear
Negative regulator of tumor cell growth via DUSP26/FADD signaling
Breast cancer cell lines and tissue samples
(54)
AK2
Lung cancer
↑
Mitochondria intermembrane space
Associated with poor survival of patients. Prognostic and therapeutic potential
Tissue samples
(55)
AK4
Lung cancer
↑
Mitochondrial matrix
Associated with poor survival of patients. Prognostic and therapeutic potential
Tissue samples and various cell lines
(56)
AK4
Glioma
↑
Mitochondrial matrix
A key regulator of intracellular ATP level. Prognostic and therapeutic potential
Tissue samples and cancer cell lines
(57)
AK6
Breast cancer Colon cancer
↑
Nuclear
Promote cancer cell growth. Prognostic and therapeutic potential
Colon adenocarcinoma and breast cancer tissues
(58)
AK6
Colon cancer
↑
Cytosol
Glycolysis regulator via phosphorylation LDHA. Modulator of CSC invasion and metastasis activity
CSC from tissues
(59)
Adenylate Kinase Modulate Tumor Cell Response to Survive Under Oxidative Stress
The ability to conduct metabolic signaling and rewire metabolism is critical for cell survival. The AK4 isoform increased expression has been associated with a poor clinical outcome marker for lung cancer (56) as well as for glioma patients (57) (see Table 1). It was found that AK4 expression is under tight control of noncoding RNA. The AK4 is negatively regulated by micro-RNA miR-556-3p and positively by circular RNA of ATP-binding cassette (ABC) subfamily B member 10, circ-ABCB10 (66). In same study was demonstrated that downregulation of AK4 restrained lung cancer progression and sensitized lung cancer cells to cisplatin (66). Moreover, new data indicate that AK4 was shown to be involved in the radioresistance of esophageal cancer cells (67) and in chemoresistance of other cancers (68, 69). Previously, it was suggested that overexpression of AK4 could protect cells against oxidative stress (70). Other studies on HeLa (68) and HEK293 cells (71) demonstrated that tumor cells respond to a hypoxic condition by upregulating the AK4. However, in HepG2 cells (71), it was found that under oxidative stress, AK4 oppositely was downregulated. Although AK4 might be downregulated, it can still regulate OXPHOS because it retains the nucleotide-binding capability, and it can interact with the mitochondrial adenine nucleotide translocase (ANT) (70). It was found that knockout of AK4 increased cellular ATP through raised OXPHOS activity as well as mitochondrial number (68). Fujisawa and colleagues in 2016 have proposed that there are two mechanisms how AK4 regulates mitochondrial respiration in cancer cells (68). First, in cancer cells, AK4 interacts with ANT, which forms with voltage-dependent anion channel (VDAC) and HK transmembrane complex AK4-ANT-VADC-HK (see Figure 1). Under the hypoxic conditions, the complex supports the high glycolytic activity of cancer cells. It allows efficient ADP recycling between mitochondrial ATP synthesis and glucose phosphorylation by HK, which interacts with the mitochondrial outer membrane (MOM) (68, 72). In addition, in hepatoma cells (73), it was found that up to 50% of ATP is provided by intramembrane space located AK2 through VDAC binding to HK. Thus, AK2 may also be a member of the metabolic circuit channeling ADP–ATP in and out of mitochondria. The second mechanism is related to the fact that AK4 and AK3 have highly homologous sequences; therefore, they compete with each other for their substrates (68). According to this mechanism, AK4 interferes with AK3 action in supplying of the GDP required for the conversion of succinyl-CoA to succinate. That is why overexpression of AK4 in HeLa cells induces a decrease in Krebs cycle metabolites such as succinate, fumarate, and malate while glutamine and glutamate are increased. In several tumors, it was shown that the predominate substrate for mitochondria is glutamine (74). However, further studies are needed to confirm the role of AK4 in mitochondria and Krebs cycle substrate metabolism.
Adenylate Kinase Network Role in Cancer Stem Cells
Traditional therapies against cancer, such as chemotherapy and radiotherapy, have many limitations. The limitation is due to systematic and local toxicity as well as drug resistance of small populations of tumor cells that have self-renewal properties. This small population of cells is called cancer stem cells (CSCs) (75). Previously, studies on CSC have shown that the cancer resistance for chemotherapy is related to increased OXPHOS in CSC. That is why a new generation of cancer chemotherapy could be targeted against pathways that interact with OXPHOS, such as the phosphotransfer system. Lamb and colleagues have shown on the breast cancer model that mitochondrial mass is a new biomarker of CSC, which have increased AK2 expression level (see Table 1) (52). In our previous study on neuroblastoma (NB) (46), which contains numerous CSC (76), and embryonal carcinoma cells (36), we also found that those cells have a high activity of AK2 (see Table 1). Moreover, another feature of CSC is that mitochondria are localized around the cell nucleus (77). There is evidence that AK2 can play an important role in communication between mitochondria and the nucleus (78). In another study using proteomic analysis of mouse teratocarcinoma cells (53), it was demonstrated that metastatic cancer cells have increased AK2 levels than have nonmetastatic cancer cells (see Table 1). As metastasis is related to cell motility, positioning of phosphotransfer enzymes to sites of increased energy consumption could be an important factor of tumor formation (59). The AK4 has been identified as a biomarker of metastasis in lung cancer (56, 79, 80). Overexpression of AK4 promoted lung cancer metastasis by enhancing hypoxia-inducible factor HIF-1 stability and epithelial-to-mesenchymal transition under hypoxia (79). Moreover, it was found that aferin-A could suppress AK4-HIF-1a signaling and may serve as a novel anti-metastatic agent in lung cancer (79). The AK4 was also implicated in breast and bladder cancers, where it promoted cell proliferation and invasion (81, 82). Furthermore, it was demonstrated that another AK isoform AK6 could affect colorectal cancer migration and invasion (59). Although significant progress has been made, at this time, the complete role of the AK system in cancer metastasis is still unclear. Moreover, the other reason why CSCs are drug resistant relates to the increased expression of ABC transporters in those cells (83, 84). The model for ABC transporters was proposed (85), which is based on 31P solid-state NMR spectroscopy, suggesting that intrinsic ATPase is coupled with AK activity where AK participates in ATP exchange. It is known that cytosolic and membrane-associated AK can regulate the activity of another ABC protein—K-ATP channel (86, 87). Nevertheless, the exact role of AK in supporting adenylate charge and function of ABC transporters in CSC remains unknown yet. In this respect, the ABC transporters are not unique proteins that possess both ATPase and AK activities; there are other proteins like AK6 (58), also known as transcription factor TAF9, human coilin interacting nuclear ATPase protein (hCINAP), and highly conserved DNA repair complex Rad50 (88).
Paradoxes Regarding the Role of Adenylate Kinase in Tumor Formation
Cancer is a very complex and diverse phenomenon, including tissue specificity and different phases. Enzymatic changes can be different in the initial and advanced stages of tumor growth (89, 90). There are some contradictory studies where it was found that in lung cancer and hepatoma, AK was downregulated compared with that in normal tissue (47, 48) (see Table 1), whereas a recent study has shown that high expression of AK2 correlates with a worse prognosis for lung cancer patients (55) (see Table 1). In mouse embryonic fibroblasts, it was demonstrated that during their transformation into tumor cells, a significant reduction of AK1 expression occurs (50). More recently, the existence of AK1 additional gene product AK1β has been reported, and it is known that the AK1β expression level is regulated by p53 (91). In some cancers, p53 is mutated or suppressed. In this context, experiments on mouse embryonic fibroblast (50) have shown that during their transformation into tumor cells, augmentation of AK1 might be related to the downregulation of AK1β (see Table 1). Also, Kim et al. have postulated that AK2 is a negative regulator of tumor growth (54) (see Table 1). They demonstrated that in some cells, the AK2 localized not only in mitochondria but also in the nucleus, where it interacted with dual-specificity phosphatase 26 (DUSP26). This protein complex can dephosphorylate FADD leading to suppressed cell growth. They also suggested that AK2 downregulation was associated with breast cancer formation. In contrast, Speers and colleagues have found that AK2 is overexpressed in ER-negative breast cancer (51) (see Table 1). They proposed that AK2 should be a novel target for the treatment of ER-negative breast cancer. Indeed, a diterpene lactone neoandrographolide from extracts of the traditional medicinal herb Andrographis paniculata has been suggested to inhibit AK2 and have strong anticancer properties (92). Nevertheless, studies on human breast cancer and colorectal cancer demonstrated another AK isoform AK6 was overexpressed during cancer formation (58) (see Table 1). These data correlate with our previous studies on colorectal and breast cancers (41, 46) (see Table 1). It was also shown, that in both colon and breast tissues, AK6 is located not only in nuclear but also in the cytosol. However, only in cytosolic compartmentalized AK6 did expression level increase during tumorogenesis of breast and colorectal cancer cells (58) (see Table 1). They have found that AK6's main function is to regulate ribosome assembly and, consequently, protein expression and cancer cell growth. Recently, it was demonstrated that hCINAP or AK6 is a potent modulator of metabolic reprogramming by phosphorylating LDHA, a key player in cancer glycolysis (59) (see Table 1). Thus, AK isoform role can be different depending on cancer cell type and development stage.
Adenylate Kinase-Mediated Amp Metabolic Signaling in Cancer Cells
In recent years, AK-mediated AMP signaling is emerging as one of the most versatile systems in the regulation of diverse cellular processes (5, 22, 93). Particularly, AMP signaling to AMP-activated protein kinase (AMPK) plays a critical role in adjusting ATP-producing and ATP-consuming processes (90, 94) (Figure 1). In several cancers, it has been demonstrated that AMPK, a master regulator of cellular energy homeostasis, possesses tumor suppressor function (95–97). In cells, AMPK activation/suppression is regulated via changes in cellular AMP levels. The principal activator of AMPK is the AK-catalyzed pathway, where it monitors cellular ATP–ADP balance and signals to AMPK by increased AMP cellular level. A recent study indicates that AK and AMPK cooperate to maintain cellular ATP levels (98). On the other end, AMP-deaminase (AMPD) and 5′-nucleotidase (5′-NT) suppress AMPK via decreasing AMP cellular levels (22, 99, 100). Moreover, the product of AMPD and 5'-NT reactions is adenosine, an immunosuppressive metabolite. At a high level in tumors, adenosine can promote cell growth, invasion, metastasis of cancer cells, and tumor immune evasion (101). Our previous work has demonstrated that in NB and heart adenocarcinoma cells HL-1, their mitochondrial permeability for AMP was increased than in healthy cells (46). It is known that AK2, which has unique localization in mitochondrial space, has a high affinity for AMP among AMP metabolizing enzymes. Therefore, it has been proposed that the AK2's primary function is to regulate intracellular AMP levels and to guard the cellular adenine nucleotide pool (22). Our study also suggested that cancer cells have a high level of AK2 (46) (Figure 1). Altogether, in cancer cells, most cellular AMP transport occurs via MOM where it is converted immediately to ADP and channeled into, maintaining a low cytosolic AMP concentration. Recent direct measurements of AK-mediated metabolic flux indicate that cancer cells have suppressed ATP β-phosphoryl energetics and AMP signaling, as indicated from 18O-labeling experiments demonstrating that highly aggressive breast cancer cells MDAMB231 have lower β-ATP[18O] turnover (AMP phosphorylation) than have the control MCF10A cells (Klepinin et al., in preparation). This could be due to the rewiring of energy metabolism and glycolytic takeover. Activated glycolysis usually suppresses AK metabolic flux apparently by scavenging ADP (102) (Figure 1). Suppression of AK phosphotransfer, AMP generation, and consequent signaling through AMPK could be the biggest culprit of a cancerous transformation of a cell (Figure 1). There is also evidence that other AMP removal pathway enzymes like AMPD2 as well as 5′-NT are upregulated in colorectal cancer (103, 104). In this regard, the 5′-NT expression in breast cancer depends on tumor estrogen receptor status, suggesting a coordinated network (105). Our previous work has shown that in several tumors, MOM permeability has also increased for ADP, which may be related with keeping an intracellular ADP level low (41, 42, 49, 106) (see Figure 1). It was found that not only AMP but also ADP can regulate the activity of AMPK (107). Further studies are needed to elucidate detailed mechanisms: (1) how increased MOM permeability for ADP and AMP and (2) raised expression of AMP metabolizing enzymes can regulate intracellular nucleotide levels and the activity of AMPK and (3) what the significance is of AMP metabolic signaling in cancer progression.
Conclusions
The present review is a snapshot from recent AK studies that focused on the significance of AK network in energetics and metabolic signaling in cancer cells. Of the nine AK isoforms (AK1–AK9), four of them (AK1, AK2, AK4, and AK6) are involved in the progression of malignant transformation. Studies indicate that AK isoforms (AK1, AK2, AK4, and AK6) have an important role in the regulation of cancer cell metabolism, metabolic signaling, and cell migration and invasion. Moreover, at the initial stage, suppression of AK phosphotransfer and AMP generation and consequently signaling through AMPK by a variety of factors could be the biggest culprit of the cancerous transformation of a cell. Downregulation of AK→ AMP→ AMPK signaling can lead to the loss of control of cell cycle, growth, and proliferation. In the later stages, as emerging data suggest, cancer cells may use the shift in AK isoforms and other phosphotransfer enzymes to rewire their energy supply circuits to support proliferation and metastasis. Knockdown of overexpressed AK2 in human lung adenocarcinoma cells suppressed proliferation, migration, and invasion as well as induced apoptosis and autophagy. In this regard, a diterpene lactone neoandrographolide from extracts of the traditional medicinal herb Andrographis paniculata has been suggested to inhibit AK2 and has strong anticancer properties. Further studies that involve all AK isoforms have the potential to bring new understanding and novel therapeutic strategies targeting the AK isoform network to suppress growth and metastasis of cancer cells.
Author Contributions
AK and SZ performed the study design, development of methodology, data analysis and interpretation, drafting of the manuscript, and critical revision. LK and ER-K analyzed and interpreted data and performed manuscript review. AT, TK, and PD performed the study conception, design, writing, and reviewing of the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
ReferencesDzejaPChungSTerzicA. Integration of adenylate kinase, glycolytic and glycogenolytic circuits in cellular energetics. In: SaksV, editor. . Weinheim: Wiley-VCH. (2007). p. 265–301. 10.1002/9783527621095.ch8DzejaPPTerzicA. Phosphotransfer networks and cellular energetics. (2003) 206:2039–47. 10.1242/jeb.0042612756286SaksVDzejaPSchlattnerUVendelinMTerzicAWallimannT. Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. (2006) 571:253–73. 10.1113/jphysiol.2005.10144416410283SaksVMongeCAnmannTDzejaP. Integrated and organized cellular energetic systems: theories of cell energetics, compartmentation and metabolic channeling. In: SaksV, editor. . Weinheim: Wiley-VCH. (2007). p. 59–109. 10.1002/9783527621095.ch3ZhangSNemutluETerzicADzejaP. Adenylate kinase isoform network: a major hub in cell energetics and metabolic signaling. system biology of metabolic and signaling networks. (2014) 16:145–62. 10.1007/978-3-642-38505-6_6DzejaPPBastPPucarDWieringaBTerzicA. Defective metabolic signaling in adenylate kinase AK1 gene knock-out hearts compromises post-ischemic coronary reflow. (2007) 282:31366–72. 10.1074/jbc.M70526820017704060DzejaPPTerzicAWieringaB. Phosphotransfer dynamics in skeletal muscle from creatine kinase gene-deleted mice. (2004) 256-257:13–27. 10.1023/B:MCBI.0000009856.23646.38JanssenEde GroofAWijersMFransenJDzejaPPTerzicA. Adenylate kinase 1 deficiency induces molecular and structural adaptations to support muscle energy metabolism. (2003) 278:12937–45. 10.1074/jbc.M21146520012562761JanssenETerzicAWieringaBDzejaPP. Impaired intracellular energetic communication in muscles from creatine kinase and adenylate kinase (M-CK/AK1) double knock-out mice. (2003) 278:30441–9. 10.1074/jbc.M30315020012730234SteeghsKBendersAOerlemansFde HaanAHeerschapARuitenbeekW. Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. (1997) 89:93–103. 10.1016/S0092-8674(00)80186-59094718van DeursenJHeerschapAOerlemansFRuitenbeekWJapPter LaakH. Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. (1993) 74:621–31. 10.1016/0092-8674(93)90510-W8358791van HorssenRJanssenEPetersWvan de PaschLLindertMMvan DommelenMM. Modulation of cell motility by spatial repositioning of enzymatic ATP/ADP exchange capacity. (2009) 284:1620–7. 10.1074/jbc.M80697420019008233HoriguchiTFukaMFujisawaKTanimuraAMiyoshiKMurakamiR. Adenylate kinase 2 deficiency limits survival and regulates various genes during larval stages of Drosophila melanogaster. (2014) 61:137–50. 10.2152/jmi.61.13724705759NomaT. Dynamics of nucleotide metabolism as a supporter of life phenomena. (2005) 52:127–36. 10.2152/jmi.52.12716167529Lagresle-PeyrouCSixEMPicardCRieux-LaucatFMichelVDitadiA. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. (2009) 41:106–11. 10.1038/ng.27819043416PannickeUHonigMHessIFriesenCHolzmannKRumpEM. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. (2009) 41:101–5. 10.1038/ng.26519043417DzejaPPChungSFaustinoRSBehfarATerzicA. Developmental enhancement of adenylate kinase-AMPK metabolic signaling axis supports stem cell cardiac differentiation. (2011) 6:e19300. 10.1371/journal.pone.001930021556322FujisawaKMurakamiRHoriguchiTNomaT. Adenylate kinase isozyme 2 is essential for growth and development of Drosophila melanogaster. (2009) 153:29–38. 10.1016/j.cbpb.2009.01.00619416704ZhangSNemutluEDzejaP. Metabolomic profiling of adenylate kinase AK1-/- and AK2+/- transgenic mice: effect of physical stress. (2010) 122:A20435.Ghaloul-GonzalezLMohsenAWKarunanidhiASeminottiBChongHMadan-KhetarpalS. Reticular dysgenesis and mitochondriopathy induced by adenylate kinase 2 deficiency with atypical presentation. (2019) 9:15739. 10.1038/s41598-019-51922-231673062PanayiotouCSolaroliNKarlssonA. The many isoforms of human adenylate kinases. (2014) 49:75–83. 10.1016/j.biocel.2014.01.01424495878DzejaPTerzicA. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. (2009) 10:1729–72. 10.3390/ijms1004172919468337DzejaPPZeleznikarRJGoldbergND. Adenylate kinase: kinetic behavior in intact cells indicates it is integral to multiple cellular processes. (1998) 184:169–82. 10.1007/978-1-4615-5653-4_139746320NodaL. Adenylate kinase. In: BoyerP, editor. . New York, NY: Academic Press. (1973). p. 279-305. 10.1016/S1874-6047(08)60068-2Van RompayARJohanssonMKarlssonA. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. (2000) 87:189–98. 10.1016/S0163-7258(00)00048-611008000HanahanDWeinbergRA. Hallmarks of cancer: the next generation. (2011) 144:646–74. 10.1016/j.cell.2011.02.01321376230ChungSArrellDKFaustinoRSTerzicADzejaPP. Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. (2010) 48:725–34. 10.1016/j.yjmcc.2009.12.01420045004FantinVRSt-PierreJLederP. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. (2006) 9:425–34. 10.1016/j.ccr.2006.04.02316766262JoseCBellanceNRossignolR. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? (2011) 1807:552–61. 10.1016/j.bbabio.2010.10.01220955683Moreno-SanchezRRodriguez-EnriquezSMarin-HernandezASaavedraE. Energy metabolism in tumor cells. (2007) 274:1393–418. 10.1111/j.1742-4658.2007.05686.x17302740Moreno-SanchezRRodriguez-EnriquezSSaavedraEMarin-HernandezAGallardo-PerezJC. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? (2009) 35:209–25. 10.1002/biof.3119449450HanCYPattenDALeeSGParksRJChanDWHarperME. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer. (2019) 58:2161–74. 10.1002/mc.2310631486135MastersC. Cellular differentiation and the microcompartmentation of glycolysis. (1991) 61:11–22. 10.1016/0047-6374(91)90003-I1779698ZahraKDeyTAshish MishraSPPandeyU. Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis. (2020) 10:159. 10.3389/fonc.2020.0015932195169KlepininAChekulayevVTimohhinaNShevchukITeppKKaldmaA. Comparative analysis of some aspects of mitochondrial metabolism in differentiated and undifferentiated neuroblastoma cells. (2014) 46:17–31. 10.1007/s10863-013-9529-524072403OunpuuLKlepininAPookMTeinoIPeetNPajuK. 2102Ep embryonal carcinoma cells have compromised respiration and shifted bioenergetic profile distinct from H9 human embryonic stem cells. (2017) 1861:2146–54. 10.1016/j.bbagen.2017.05.02028552560GellerichFNGizatullinaZTrumbeckaiteSNguyenHPPallasTArandarcikaiteO. The regulation of OXPHOS by extramitochondrial calcium. (2010) 1797:1018–27. 10.1016/j.bbabio.2010.02.00520144582LiXHChenXJOuWBZhangQLvZRZhanY. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. (2013) 45:979–86. 10.1016/j.biocel.2013.02.00323416112DewarBJKeshariKJeffriesRDzejaPGravesLMMacdonaldJM. Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy. (2010) 6:439–50. 10.1007/s11306-010-0204-020676217MooneySMRajagopalanKWilliamsBHZengYChristudassCSLiY. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. (2011) 112:1066–75. 10.1002/jcb.2302021308735KaldmaAKlepininAChekulayevVMadoKShevchukITimohhinaN. An in situ study of bioenergetic properties of human colorectal cancer: the regulation of mitochondrial respiration and distribution of flux control among the components of ATP synthasome. (2014) 55:171–86. 10.1016/j.biocel.2014.09.00425218857KaambreTChekulayevVShevchukIKaru-VarikmaaMTimohhinaNTeppK. Metabolic control analysis of cellular respiration in situ in intraoperational samples of human breast cancer. (2012) 44:539–58. 10.1007/s10863-012-9457-922836527AmamotoRUchiumiTYagiMMonjiKSongYOdaY. The expression of ubiquitous mitochondrial creatine kinase is downregulated as prostate cancer progression. (2016) 7:50–9. 10.7150/jca.1320726722360PatraSBeraSSinhaRoySGhoshalSRaySBasuA. Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma. (2008) 275:3236–47. 10.1111/j.1742-4658.2008.06475.x18485002LamYWYuanYIsaacJBabuCVMellerJHoSM. Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. (2010) 5:e9075. 10.1371/journal.pone.000907520140087KlepininAOunpuuLGuzunRChekulayevVTimohhinaNTeppK. Simple oxygraphic analysis for the presence of adenylate kinase 1 and 2 in normal and tumor cells. (2016) 48:531–48. 10.1007/s10863-016-9687-327854030BalinskyDGreengardOCayanisEHeadJF. Enzyme activities and isozyme patterns in human lung tumors. (1984) 44:1058–62. 6692392CrissWELitwackGMorrisHPWeinhouseS. Adenosine triphosphate: adenosine monophosphate phosphotransferase isozymes in rat liver and hepatomas. (1970) 30:370–5. 4394072ChekulayevVMadoKShevchukIKoitAKaldmaAKlepininA. Metabolic remodeling in human colorectal cancer and surrounding tissues: alterations in regulation of mitochondrial respiration and metabolic fluxes. (2015) 4:111–25. 10.1016/j.bbrep.2015.08.02029124194VasseurSMalicetCCalvoELDagornJCIovannaJL. Gene expression profiling of tumours derived from ras(V12)/EIA-transformed mouse embryonic fibroblasts to identify genes required for tumour development. (2005) 4:4. 10.1186/1476-4598-4-4SpeersCTsimelzonASextonKHerrickAMGutierrezCCulhaneA. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. (2009) 15:6327–40. 10.1158/1078-0432.CCR-09-110719808870LambRBonuccelliGOzsvariBPeiris-PagesMFiorilloMSmithDL. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. (2015) 6:30453–71. 10.18632/oncotarget.585226421711RoesliCBorgiaBSchhemannCGunthertMWunderli-AllenspachHGiavazziR. Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. (2009) 69:5406–14. 10.1158/0008-5472.CAN-08-099919491280KimHLeeHJOhYChoiSGHongSHKimHJ. The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth. (2014) 5:4351. 10.1038/ncomms435124548998LiuHPuYAminaQWangQZhangMSongJ. Prognostic and therapeutic potential of Adenylate kinase 2 in lung adenocarcinoma. (2019) 9:17757. 10.1038/s41598-019-53594-431780678JanYHTsaiHYYangCJHuangMSYangYFLaiTC. Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. (2012) 72:5119–29. 10.1158/0008-5472.CAN-12-184223002211LanningNJLooyengaBDKauffmanALNiemiNMSudderthJDeBerardinisRJ. A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of ATP levels. (2014) 7:907–17. 10.1016/j.celrep.2014.03.06524767988BaiDMZhangJFLiTTHangRLLiuYTianYL. The ATPase hCINAP regulates 18S rRNA processing and is essential for embryogenesis and tumour growth. (2016) 7:12310. 10.1038/ncomms1231027477389JiYYangCTangZYangYTianYYaoH. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. (2017) 8:15308. 10.1038/ncomms15308HanselDERahmanAHouseMAshfaqRBergKYeoCJ. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. (2004) 10(18 Pt 1):6152–8. 10.1158/1078-0432.CCR-04-028515448002KarhemoPRHyvonenMLaakkonenP. Metastasis-associated cell surface oncoproteomics. (2012) 3:192. 10.3389/fphar.2012.0019223162466LeeHJPyoJOOhYKimHJHongSHJeonYJ. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. (2007) 9:1303–10. 10.1038/ncb165017952061KumariRDeshmukhRSDasS. Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis. (2019) 10:4255. 10.1038/s41467-019-12194-631534141OshimaKSaikiNTanakaMImamuraHNiwaATanimuraA. Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. (2018) 497:719–25. 10.1016/j.bbrc.2018.02.13929462620DzejaPPHoyerKTianRZhangSNemutluESpindlerM. Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency. (2011) 589:5193–211. 10.1113/jphysiol.2011.21282921878522WuZGongQYuYZhuJLiW. Knockdown of circ-ABCB10 promotes sensitivity of lung cancer cells to cisplatin via miR-556-3p/AK4 axis. (2020) 20:10. 10.1186/s12890-019-1035-z31931771ZangCZhaoFHuaLPuY. The miR-199a-3p regulates the radioresistance of esophageal cancer cells via targeting the AK4 gene. (2018) 18:186. 10.1186/s12935-018-0689-630479565FujisawaKTeraiSTakamiTYamamotoNYamasakiTMatsumotoT. Modulation of anti-cancer drug sensitivity through the regulation of mitochondrial activity by adenylate kinase 4. (2016) 35:48. 10.1186/s13046-016-0322-226980435LeiWYanCYaJYongDYujunBKaiL. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. (2018) 18:631. 10.1186/s12885-018-4460-029866054LiuRJStromALZhaiJJGalJBaoSLGongWM. Enzymatically inactive adenylate kinase 4 interacts with mitochondrial ADP/ATP translocase. (2009) 41:1371–80. 10.1016/j.biocel.2008.12.00219130895KongFBinasBMoonJHKangSSKimHJ. Differential expression of adenylate kinase 4 in the context of disparate stress response strategies of HEK293 and HepG2 cells. (2013) 533:11–7. 10.1016/j.abb.2013.02.01423474458PedersenPL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. (2007) 39:211–22. 10.1007/s10863-007-9094-x17879147NelsonBDKabirF. Adenylate Kinase Is a Source of Atp for Tumor Mitochondrial Hexokinase. (1985) 841:195–200. 10.1016/0304-4165(85)90021-22990572ChoiYKParkKG. Targeting Glutamine Metabolism for Cancer Treatment. (2018) 26:19–28. 10.4062/biomolther.2017.17829212303DeshmukhADeshpandeKArfusoFNewsholmePDharmarajanA. Cancer stem cell metabolism: a potential target for cancer therapy. (2016) 15:555. 10.1186/s12943-016-0555-x27825361RossRASpenglerBA. Human neuroblastoma stem cells. (2007) 17:241–7. 10.1016/j.semcancer.2006.04.00616839774SongISJeongJYJeongSHKimHKKoKSRheeBD. Mitochondria as therapeutic targets for cancer stem cells. (2015) 7:418–27. 10.4252/wjsc.v7.i2.41825815125DzejaPPBortolonRPerez-TerzicCHolmuhamedovELTerzicA. Energetic communication between mitochondria and nucleus directed by catalyzed phosphotransfer. (2002) 99:10156–61. 10.1073/pnas.15225999912119406JanYHLaiTCYangCJLinYFHuangMSHsiaoM. Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1alpha to drive lung adenocarcinoma metastasis. (2019) 12:12. 10.1186/s13045-019-0698-530696468JanYHLaiTCYangCJHuangMSHsiaoM. A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. (2019) 9:12329. 10.1038/s41598-019-48243-931444368XinFYaoDWFanLLiuJHLiuXD. Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion. (2019) 19:525–34. 10.1007/s10238-019-00576-531463832ZhangJYinYTWuCHQiuRLJiangWJDengXG. AK4 promotes the progression of HER2-positive breast cancer by facilitating cell proliferation and invasion. (2019) 2019:8186091. 10.1155/2019/818609131827645SchattonTMurphyGFFrankNYYamauraKWaaga-GasserAMGasserM. Identification of cells initiating human melanomas. (2008) 451:345–U11. 10.1038/nature0648918202660AdamsJMStrasserA. Is tumor growth sustained by rare cancer stem cells or dominant clones? (2008) 68:4018–21. 10.1158/0008-5472.CAN-07-6334KaurHLakatos-KarolyAVogelRNollATampeRGlaubitzC. Coupled ATPase-adenylate kinase activity in ABC transporters. (2016) 7:13864. 10.1038/ncomms1386428004795DzejaPPTerzicA. Phosphotransfer reactions in the regulation of ATP-sensitive K+ channels. (1998) 12:523–9. 10.1096/fasebj.12.7.5239576479CarrascoAJDzejaPPAlekseevAEPucarDZingmanLVAbrahamMR. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. (2001) 98:7623–8. 10.1073/pnas.12103819811390963BhaskaraVDupreALengsfeldBHopkinsBBChanALeeJH. Rad50 adenylate kinase activity regulates DNA tethering by Mre11/Rad50 complexes. (2007) 25:647–61. 10.1016/j.molcel.2007.01.02817349953BoissanMSchlattnerULacombeML. The NDPK/NME superfamily: state of the art. (2018) 98:164–74. 10.1038/labinvest.2017.13729451272GonzalezAHallMNLinSCHardieDG. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. (2020) 31:472–92. 10.1016/j.cmet.2020.01.01532130880CollavinLLazarevicDUtreraRMarzinottoSMonteMSchneiderC. wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. (1999) 18:5879–88. 10.1038/sj.onc.120297010557075SholihahMMIndartoDPramanaTY. The inhibitory effect ofAndrographis paniculataextract on proliferation of breast cancer cell line. (2019) 546:062029. 10.1088/1757-899X/546/6/062029HardieDG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. (2011) 39:1–13. 10.1042/BST039000121265739HardieDG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. (2007) 8:774–85. 10.1038/nrm224917712357DasguptaBChhipaRR. Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer. (2016) 37:192–206. 10.1016/j.tips.2015.11.00726711141HardieDGAlessiDR. LKB1 and AMPK and the cancer-metabolism link - ten years after. (2013) 11:36. 10.1186/1741-7007-11-3623587167ShackelfordDBShawRJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. (2009) 9:563–75. 10.1038/nrc267619629071TakaineMImamuraHYoshidaS. AMP-activated protein kinase and adenylate kinase prevent the ATP catastrophe and cytotoxic protein aggregation. (2019) 801738. 10.1101/801738PlaideauCLiuJMHartleib-GeschwindnerJBastin-CoyetteLBontempsFOscarssonJ. Overexpression of AMP-metabolizing enzymes controls adenine nucleotide levels and AMPK activation in HEK293T cells. (2012) 26:2685–94. 10.1096/fj.11-19816822415305PlaideauCLaiYCKviklyteSZanouNLofgrenLAndersenH. Effects of pharmacological amp deaminase inhibition and ampd1 deletion on nucleotide levels and AMPK activation in contracting skeletal muscle. (2014) 21:1497–510. 10.1016/j.chembiol.2014.09.01325459662LeoneRDEmensLA. Targeting adenosine for cancer immunotherapy. (2018) 6:57. 10.1186/s40425-018-0360-829914571OlsonLKSchroederWRobertsonRPGoldbergNDWalsethTF. Suppression of adenylate kinase catalyzed phosphotransfer precedes and is associated with glucose-induced insulin secretion in intact HIT-T15 cells. (1996) 271:16544–52. 10.1074/jbc.271.28.165448663240WangFLiuYJiangJQinYGeXLiJ. High expression of AMPD2 and obesity are associated with poor prognosis in colorectal cancer. (2018) 11:216–23. 31938103ParrCJiangWG. Quantitative analysis of lymphangiogenic markers in human colorectal cancer. (2003) 23:533–9. 10.3892/ijo.23.2.53312851706SpychalaJLazarowskiEOstapkowiczAAyscueLHJinAMitchellBS. Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. (2004) 10:708–17. 10.1158/1078-0432.CCR-0811-0314760094KlepininAOunpuuLMadoKTruuLChekulayevVPuurandM. The complexity of mitochondrial outer membrane permeability and VDAC regulation by associated proteins. (2018) 50:339–54. 10.1007/s10863-018-9765-929998379XiaoBSandersMJUnderwoodEHeathRMayerFVCarmenaD. Structure of mammalian AMPK and its regulation by ADP. (2011) 472:230–3. 10.1038/nature0993221399626AbbreviationsAK
adenylate kinase
CK
creatine kinase
CKmit
mitochondrial creatine kinase
CKB
brain-type creatine kinase
MOM
mitochondrial outer membrane
ANT
adenine nucleotide translocase
AMPK
AMP-activated protein kinase
CSCs
cancer stem cells
NB
neuroblastoma
VDAC
voltage-dependent anion channel
ABC
ATP-binding cassette
FADD
Fas-associated protein with death domain
HIF
hypoxia-inducible factor
hCINAP
human coilin-interacting nuclear ATPase protein
DUSP26
dual-specificity phosphatase 26
OXPHOS
oxidative phosphorylation
AMPD
AMP-deaminase
5′-NT
5′-nucleotidase
LDHA
lactate dehydrogenase A
HK
hexokinase.
Funding. This work was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (HL 85744-09) and U24DK100469 (Mayo Clinic Metabolomics Resource Core); Marriott Foundation and Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; Institutional Research Funding IUT23-1 of the Estonian Ministry of Education and Research; and Estonia national scholarship program Kristjan Jaak, which is funded and managed by Archimedes Foundation in collaboration with the Estonian Ministry of Education and Research.